

Prediction of overall survival in stage II and III colon ca retrospective, pooled biomarker study

Annals of Oncology

28, 1023-1031

DOI: [10.1093/annonc/mdx052](https://doi.org/10.1093/annonc/mdx052)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Including Lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer. <i>Annals of Oncology</i> , 2017, 28, 2620-2621.	0.6	2
2	Reply to the letter to the editor "Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer"™ by Sciallero et al.. <i>Annals of Oncology</i> , 2017, 28, 2889-2890.	0.6	0
3	Neoantigen Targeting" Dawn of a New Era in Cancer Immunotherapy?. <i>Frontiers in Immunology</i> , 2017, 8, 1848.	2.2	73
4	CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. <i>Annals of Oncology</i> , 2018, 29, 1227-1234.	0.6	63
5	The Prognostic Relevance of Sentinel Lymph Node Metastases Assessed by PHGR1 mRNA Quantification in Stage I to III Colon Cancer. <i>Translational Oncology</i> , 2018, 11, 436-443.	1.7	2
6	Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. <i>European Journal of Cancer</i> , 2018, 92, 1-10.	1.3	14
7	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 696-703.	1.1	11
8	Precision Medicine Versus Population Medicine in Colon Cancer: From Prospects of Prevention, Adjuvant Chemotherapy, and Surveillance. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 220-230.	1.8	7
9	Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification. <i>JAMA Network Open</i> , 2018, 1, e183115.	2.8	24
10	Prognostic value of the combination of microsatellite instability and BRAF mutation in colorectal cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 3911-3929.	0.9	22
11	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 635-643.	3.7	60
12	Real-World Implications of Nonbiological Factors with Staging, Prognosis and Clinical Management in Colon Cancer. <i>Cancers</i> , 2018, 10, 263.	1.7	15
13	Prognostic significance of CEACAM5 mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 767-775.	1.1	19
14	Clinical significance of the BRAFV600E mutation in Asian patients with colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2018, 33, 1173-1181.	1.0	11
15	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. <i>British Journal of Cancer</i> , 2018, 118, 1609-1616.	2.9	47
16	Alternative splicing expands the prognostic impact of <i>KRAS</i> in microsatellite stable primary colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 841-847.	2.3	26
17	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. <i>British Journal of Cancer</i> , 2019, 121, 474-482.	2.9	41
18	LINC00957 Acted as Prognostic Marker Was Associated With Fluorouracil Resistance in Human Colorectal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 776.	1.3	24

#	ARTICLE	IF	CITATIONS
19	An immune infiltration signature to predict the overall survival of patients with colon cancer. <i>IUBMB Life</i> , 2019, 71, 1760-1770.	1.5	67
20	External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS. <i>BMC Cancer</i> , 2019, 19, 681.	1.1	18
21	Molecular targeted therapy of <i>BRAF</i> -mutant colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985649.	1.4	72
22	Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, 1622-1629.	0.6	150
23	Differences and overlap in plasma protein expression during colorectal cancer progression. <i>Translational Medicine Communications</i> , 2019, 4, .	0.5	5
24	Proteome-transcriptome alignment of molecular portraits achieved by self-contained gene set analysis: Consensus colon cancer subtypes case study. <i>PLoS ONE</i> , 2019, 14, e0221444.	1.1	1
25	Is the tumour microenvironment a critical prognostic factor in early-stage colorectal cancer?. <i>Annals of Oncology</i> , 2019, 30, 1538-1540.	0.6	4
26	The prognostic value of hypoxia-inducible factor-1 α in advanced cancer survivors: a meta-analysis with trial sequential analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987585.	1.4	17
27	Colorectal Cancer Prognosis Is Not Associated with BRAF and KRAS Mutations-A STROBE Compliant Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 111.	1.0	12
28	Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. <i>Oncogenesis</i> , 2019, 8, 35.	2.1	19
29	Identification of several plasma proteins whose levels in colorectal cancer patients differ depending on outcome. <i>FASEB BioAdvances</i> , 2019, 1, 723-730.	1.3	7
30	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. <i>ESMO Open</i> , 2019, 4, e000523.	2.0	11
31	Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) Is Not Attributed to MSH3 Loss in Stage I-III Colon cancer: An Automated, Digitalized Assessment by Immunohistochemistry of Whole Slides and Hot Spots. <i>Translational Oncology</i> , 2019, 12, 1583-1588.	1.7	7
32	Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. <i>Cancers</i> , 2019, 11, 2003.	1.7	11
33	Molecular subtyping improves prognostication of Stage 2 colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1155.	1.1	13
35	Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients. <i>International Journal of Clinical Oncology</i> , 2019, 24, 141-152.	1.0	19
36	Concomitant dysregulation of the estrogen receptor and BRAF/MEK signaling pathways is common in colorectal cancer and predicts a worse prognosis. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 197-209.	2.1	8
37	Associations Between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 402-410.e2.	2.4	44

#	ARTICLE	IF	CITATIONS
38	Biomarker-guided therapy for colorectal cancer: strength in complexity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 11-32.	12.5	195
39	Elevated Microsatellite Alterations at Selected Tetranucleotides (EMAST) in Colorectal Cancer is Associated with an Elderly, Frail Phenotype and Improved Recurrence-Free Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 1058-1067.	0.7	14
40	High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 237-247.	2.1	3
41	Low Socioeconomic Status Is Associated with Worse Outcomes After Curative Surgery for Colorectal Cancer: Results from a Large, Multicenter Study. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2628-2636.	0.9	27
42	Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis. <i>PLoS Medicine</i> , 2020, 17, e1003292.	3.9	25
43	Identification of Genomic Alterations of Perineural Invasion in Patients with Stage II Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11571-11582.	1.0	3
44	Prognostic Values of Preoperative Inflammatory and Nutritional Markers for Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 585083.	1.3	10
45	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. <i>ESMO Open</i> , 2020, 5, e001040.	2.0	6
46	A Novel Prognostic Model Incorporating Carcinoembryonic Antigen in 3-Week or Longer Postoperative Period for Stage III Colon Cancer: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2020, 10, 566784.	1.3	5
47	Construction and Validation of a Cell Cycle-Related Robust Prognostic Signature in Colon Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 611222.	1.8	8
48	An easily adaptable validated risk score predicts cancer-specific survival in stage II colon cancer. <i>Acta Oncologica</i> , 2020, 59, 1503-1507.	0.8	2
49	Molecular Biomarkers according to Primary Tumor Location in Colorectal Cancer: Current Standard and New Insights. <i>Oncology</i> , 2021, 99, 135-143.	0.9	15
50	Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 850.	1.1	14
51	Which patients to sample in clinical cohort studies when the number of events is high and measurement of additional markers is constrained by limited resources. <i>Cancer Medicine</i> , 2020, 9, 7398-7406.	1.3	5
52	Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients. <i>Cancers</i> , 2020, 12, 2289.	1.7	14
53	One-year mortality of colorectal cancer patients: development and validation of a prediction model using linked national electronic data. <i>British Journal of Cancer</i> , 2020, 123, 1474-1480.	2.9	2
54	Adjuvant Chemotherapy for Stage II Colon Cancer. <i>Cancers</i> , 2020, 12, 2584.	1.7	27
55	Outcomes of Adjuvant Oral versus Intravenous Fluoropyrimidines for High-Risk Stage II or Stage III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study. <i>Journal of Cancer</i> , 2020, 11, 4157-4165.	1.2	1

#	ARTICLE	IF	CITATIONS
56	Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2533-2546.	2.0	31
57	Redefining Colorectal Cancer by Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 147-159.	1.8	9
58	Endosialin (TEM1) as a Diagnostic, Progression, and Prognostic Serum Marker for Patients With Colorectal Cancer—A Preliminary Study. <i>Cancer Control</i> , 2020, 27, 107327482090335.	0.7	6
59	Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies. <i>Gastroenterology</i> , 2020, 158, 2158-2168.e4.	0.6	34
60	Precision Therapy in RAS Mutant Colorectal Cancer. <i>Gastroenterology</i> , 2020, 158, 806-811.	0.6	29
61	Monoamine Oxidase B Expression Correlates with a Poor Prognosis in Colorectal Cancer Patients and Is Significantly Associated with Epithelial-to-Mesenchymal Transition-Related Gene Signatures. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2813.	1.8	25
62	The Long Non-Coding RNA-RoR Promotes the Tumorigenesis of Human Colorectal Cancer by Targeting miR-6833-3p Through SMC4. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2573-2581.	1.0	16
63	The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. <i>British Journal of Cancer</i> , 2021, 124, 786-796.	2.9	11
64	Tumor microenvironment derived signature predicting relapse-free survival in HII cancer and preliminary experiment verification. <i>International Immunopharmacology</i> , 2021, 91, 107243.	1.7	4
65	New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 65-79.	1.4	4
66	Six mutator-derived lncRNA signature of genome instability for predicting the clinical outcome of colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 0-0.	0.6	4
67	Is Microsatellite Status Associated With Prognosis in Stage II Colon Cancer With High-Risk Features?. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 545-554.	0.7	3
68	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. <i>Advances in Cancer Research</i> , 2021, 151, 231-304.	1.9	8
69	Identification of biomarkers related to Tumor-Infiltrating Lymphocytes (TILs) infiltration with gene co-expression network in colorectal cancer. <i>Bioengineered</i> , 2021, 12, 1676-1688.	1.4	9
70	PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells. <i>Gut</i> , 2022, 71, 119-128.	6.1	46
71	Recent Therapeutic Strategies for the Treatment of Colon Cancer. , 2021, , 73-90.		0
72	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	0.8	84
73	Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3863-3872.	1.2	8

#	ARTICLE	IF	CITATIONS
74	Prognostic implications of an autophagy-based signature in colorectal cancer. <i>Medicine (United States)</i> , 2021, 100, 1-10. doi:10.1093/med/100.1.1	0.4	9
75	Concomitant Mutations G12D and G13D on the Exon 2 of the KRAS Gene: Two Cases of Women with Colon Adenocarcinoma. <i>Diagnostics</i> , 2021, 11, 659.	1.3	4
76	Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study. <i>World Journal of Surgical Oncology</i> , 2021, 19, 96.	0.8	41
77	MTBP promoted the proliferation, migration and invasion of colon cancer cells by activating the expression of ZEB2. <i>Animal Cells and Systems</i> , 2021, 25, 152-160.	0.8	8
78	Feature Selection for Polygenic Risk Scores using Genetic Algorithm and Network Science. , 2021, , .		2
79	Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3130.	1.7	13
80	Genetic and biological hallmarks of colorectal cancer. <i>Genes and Development</i> , 2021, 35, 787-820.	2.7	159
81	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. <i>Cancers</i> , 2021, 13, 2762.	1.7	14
82	Predicting Microsatellite Instability Status in Colorectal Cancer Based on Triphasic Enhanced Computed Tomography Radiomics Signatures: A Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 687771.	1.3	21
83	HS3ST2 and Its Related Molecules as Potential Biomarkers for Predicting Lymph Node Metastasis in Patients with Colorectal Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3881-3894.	1.0	2
84	Identification of the miRNA signature and key genes in colorectal cancer lymph node metastasis. <i>Cancer Cell International</i> , 2021, 21, 358.	1.8	11
85	Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer. <i>Cancer Science</i> , 2021, 112, 3856-3870.	1.7	9
86	Addition of V-Stage to Conventional TNM Staging to Create the TNVM Staging System for Accurate Prediction of Prognosis in Colon Cancer: A Multi-Institutional Retrospective Cohort Study. <i>Biomedicine</i> , 2021, 9, 888.	1.4	2
87	A methylation-driven gene panel predicts survival in patients with colon cancer. <i>FEBS Open Bio</i> , 2021, 11, 2490-2506.	1.0	6
88	Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1034-1040.	0.4	3
89	How I treat stage II colon cancer patients. <i>ESMO Open</i> , 2021, 6, 100184.	2.0	14
90	Long intragenic non-coding RNA p53-induced transcript (LINC-PINT) as a novel prognosis indicator and therapeutic target in cancer. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112127.	2.5	17
91	Identification of an exosomal long non-coding RNAs panel for predicting recurrence risk in patients with colorectal cancer. <i>Aging</i> , 2020, 12, 6067-6088.	1.4	8

#	ARTICLE	IF	CITATIONS
92	Analysis of a gene panel for targeted sequencing of colorectal cancer samples. <i>Oncotarget</i> , 2018, 9, 9043-9060.	0.8	8
93	Combined assessment of the TNM stage and <i>BRAF</i> mutational status at diagnosis in sporadic colorectal cancer patients. <i>Oncotarget</i> , 2018, 9, 24081-24096.	0.8	12
94	Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. <i>Journal of Cancer Metastasis and Treatment</i> , 2018, 4, 12.	0.5	5
95	Possible Enhancement of Photodynamic Therapy (PDT) Colorectal Cancer Treatment when Combined with Cannabidiol. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2021, 21, 137-148.	0.9	19
96	<i>PNN</i> and <i>KCNQ1OT1</i> Can Predict the Efficacy of Adjuvant Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer Patients. <i>Oncology Research</i> , 2020, 28, 631-644.	0.6	10
97	Prognostic Factors for Post-Recurrence Survival in Stage II and III Colorectal Carcinoma Patients. <i>Medicina (Lithuania)</i> , 2021, 57, 1108.	0.8	10
98	Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2022, 126, 48-56.	2.9	8
100	Development and Validation of the Individualized Prognostic Nomograms in Patients With Right- and Left-Sided Colon Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 709835.	1.3	4
101	Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. <i>Molecular Cancer</i> , 2021, 20, 143.	7.9	117
102	State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 451-462.	3.0	2
103	The prognostic significance of FBXO2 expression in colorectal cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 5054-5062.	0.5	2
104	Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 735-745.	0.3	59
105	Circumferential Resection Margin is Associated with Distant Metastasis After Rectal Cancer Surgery. <i>Annals of Surgery</i> , 2021, Publish Ahead of Print, .	2.1	7
106	Expression of proteins associated with the Warburg effect and survival in colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 169-180.	1.3	11
107	Exploring Serum NMR-Based Metabolomic Fingerprint of Colorectal Cancer Patients: Effects of Surgery and Possible Associations with Cancer Relapse. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 11120.	1.3	3
108	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. <i>Cancers</i> , 2021, 13, 5750.	1.7	4
109	Oncotype DX testing does not affect clinical practice in stage IIa colon cancer. <i>Medical Oncology</i> , 2022, 39, 59.	1.2	2
110	Adjuvant chemotherapy for stage II colon cancer: Whom to treat?. <i>Journal of Current Oncology</i> , 2021, 4, 102.	0.2	0

#	ARTICLE	IF	CITATIONS
111	Molecular Classifications of Gastrointestinal Tract Tumors. , 2022, , 943-977.		0
112	Clinical Significance of Genetic Variants in Colon Cancer. , 2022, , 69-91.		1
113	Differential DNA methylation analysis of <i>SUMF2</i> , <i>ADAMTS5</i> , and <i>PXDN</i> provides novel insights into colorectal cancer prognosis prediction in Taiwan. World Journal of Gastroenterology, 2022, 28, 825-839.	1.4	6
114	KRAS Assessment Following ESMO Recommendations for Colorectal Liver Metastases. Is It Always Worth It?. Healthcare (Switzerland), 2022, 10, 472.	1.0	1
115	Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2022, 40, 892-910.	0.8	85
116	Comprehensive Analysis of Colorectal Cancer Immunity and Identification of Immune-Related Prognostic Targets. Disease Markers, 2022, 2022, 1-13.	0.6	3
117	Prothrombin time (PT) and CEA as prognostic predictive biomarkers for postoperative recurrence after curative resection in patients with stage III colorectal cancer: a retrospective cohort study. Updates in Surgery, 2022, 74, 999-1009.	0.9	5
118	KRAS: A Druggable Target in Colon Cancer Patients. International Journal of Molecular Sciences, 2022, 23, 4120.	1.8	13
119	Defects in MMR Genes as a Seminal Example of Personalized Medicine: From Diagnosis to Therapy. Journal of Personalized Medicine, 2021, 11, 1333.	1.1	9
120	MicroRNA-363-3p, negatively regulated by long non-coding RNA small nucleolar RNA host gene 5, inhibits tumor progression by targeting Aurora kinase A in colorectal cancer. Bioengineered, 2022, 13, 5357-5372.	1.4	4
121	Pan-cancer prognostic genetic mutations and clinicopathological factors associated with survival outcomes: a systematic review. Npj Precision Oncology, 2022, 6, 27.	2.3	19
122	Development and external validation of a novel nomogram for predicting cancer-specific survival in patients with ascending colon adenocarcinoma after surgery: a population-based study. World Journal of Surgical Oncology, 2022, 20, 126.	0.8	2
128	Effect of oxaliplatin in elderly colon cancer patients with pathological T4 and/or N2 disease: a multicenter, propensity score-matched analysis. International Journal of Colorectal Disease, 2022, 37, 1181-1188.	1.0	2
129	New Insights into Adjuvant Therapy for Localized Colon Cancer. Hematology/Oncology Clinics of North America, 2022, , .	0.9	1
130	Microsatellite instability and chemosensitivity in solid tumours. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210993.	1.4	8
131	The relationship between the Glasgow Microenvironment Score and markers of epithelial-mesenchymal transition in TNM II-III colorectal cancer. Human Pathology, 2022, 127, 1-11.	1.1	2
132	Temporal Trends in Clinical Evidence of 5-Year Survival Within Electronic Health Records Among Patients With Early-Stage Colon Cancer Managed With Laparoscopy-Assisted Colectomy vs Open Colectomy. JAMA Network Open, 2022, 5, e2218371.	2.8	4
133	Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treatment Reviews, 2022, 109, 102433.	3.4	15

#	ARTICLE	IF	CITATIONS
134	Prognostic and predictive molecular biomarkers in advanced colorectal cancer. , 2022, 236, 108239.		17
135	Identification of fatty acid metabolism-related lncRNAs in the prognosis and immune microenvironment of colon adenocarcinoma. <i>Biology Direct</i> , 2022, 17, .	1.9	4
136	KRAS mutation status between left- and right-sided colorectal cancer: are there any differences in computed tomography?. <i>Japanese Journal of Radiology</i> , 2023, 41, 83-91.	1.0	1
137	Microsatellite instability in colon cancer: A single center experience from North India. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 656.	0.3	0
138	The Prognostic Utilities of DNA Mismatch Repair Status and KRAS and BRAF Mutation in Korean Colorectal Cancer Patients: The KASID Multicenter Study. <i>Oncology</i> , 2023, 101, 49-58.	0.9	2
141	The Glasgow Microenvironment Score and risk and site of recurrence in TNM III colorectal cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	0
142	Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	0
143	Effect of Jianpi Bushen formulae for colon cancer patients who underwent adjuvant chemotherapy: Statistical analysis plan for a multicenter trial. <i>Journal of Traditional Chinese Medical Sciences</i> , 2022, , .	0.1	0
144	Transcriptomic Profiling Reveals an Enhancer RNA Signature for Recurrence Prediction in Colorectal Cancer. <i>Genes</i> , 2023, 14, 137.	1.0	0
145	Gut Microbiome and Immune Responses in Gastrointestinal Cancer. , 2023, , 163-179.		0
146	Fast and label-free automated detection of microsatellite status in early colon cancer using artificial intelligence integrated infrared imaging. <i>European Journal of Cancer</i> , 2023, 182, 122-131.	1.3	6
148	What is precision medicine in oncology?. , 2023, , 1-30.		0
149	Combining of immunotherapeutic approaches with chemotherapy for treatment of gastric cancer: Achievements and limitations. <i>International Immunopharmacology</i> , 2023, 118, 110062.	1.7	6
150	The E3 ubiquitin ligase SCF (FBXW10)-mediated LATS2 degradation regulates angiogenesis and liver metastasis in colorectal cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2023, 158, 106408.	1.2	1
151	NSPA: characterizing the disease association of multiple genetic interactions at single-subject resolution. <i>Bioinformatics Advances</i> , 2023, 3, .	0.9	0
152	Prognostic Nomogram for Colorectal Cancer Patients After Surgery. <i>Indian Journal of Surgery</i> , 0, , .	0.2	0
153	SCF-FBXL8 contributes to liver metastasis and stem cell-like features in colorectal cancer cells by mediating ubiquitination and degradation of TP53. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	2
154	Prioritizing prognostic-associated subpopulations and individualized recurrence risk signatures from single-cell transcriptomes of colorectal cancer. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	2

#	ARTICLE	IF	CITATIONS
155	Association of collagen deep learning classifier with prognosis and chemotherapy benefits in stage colon cancer. Bioengineering and Translational Medicine, 2023, 8, .	3.9	3